Stock of the week: Apiam delivering strong revenue and earnings growth


Published 04-OCT-2018 15:51 P.M.


8 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

While the excitement that surrounds the potential success of a mining company’s drilling results, a biotech’s trials or an IT company’s new proprietary software is always interesting, and definitely throws up investment ideas, sometimes it’s good to get back to an entity with predictable earnings that is easy to understand. Our stock of the week is such a company.

Apiam Animal Health (ASX:AHX) operates in the Australian animal health market where it provides products and services to both commercial livestock and companion animals. The company's vertically integrated business model facilitates the generation of revenues from production of goods through to the provision of veterinary services, as well as the wholesaling and retailing of animal products and feeds.

Apiam’s strategy is to service animals throughout their lifecycle, including the provision of veterinary services, ancillary services, genetics, wholesale and retail of related products, together with technical services related to food-chain security.

The company has 43 clinics located throughout Australia, employing more than 150 veterinarians.

Improved efficiencies drive margin growth

Apiam delivered underlying earnings growth of 17.2% in fiscal 2018 on the back of revenue growth of 4% excluding acquisitions.

This highlights the fact that the company is achieving margin growth through management’s initiatives to achieve efficiencies in the underlying business, as well as effectively integrating newly acquired complementary businesses.

Looking across the fiscal 2018 performance, one of the standout features was the substantial uplift in operating cash flow which increased from $7.5 million in fiscal 2017 to $9.2 million.

Management expects this strong cash conversion to continue in fiscal 2019, providing the company with the balance sheet strength to make further acquisitions while investing in its core business with a view to achieving solid organic growth.

Continues to grow established business

This is an important aspect in terms of Apiam’s long-term prospects, as history shows that companies which are overly reliant on acquisitions to generate growth often finish up laden with debt with nowhere to go as the business has grown in size but is floundering from an operational perspective.

Apiam’s focus on efficiencies, cost management and investing in growth is evidenced in the following comments by managing director Dr Chris Richards who said, “Apiam has delivered another year of solid revenue growth, with underlying revenue growth delivered in each of our animal divisions.

“The strong uplift in our underlying EBITDA margin reflects that our vertically integrated strategy is working, and that our corporate operating infrastructure is now beginning to deliver early stage cost efficiencies and savings as the business grows.

“We have also generated strong cash flows over the period, which are funding our continued re-investment in business growth, particularly our acquisitions and capital expenditure program.

“The business is well placed to deliver additional revenue and earnings growth in fiscal 2019, particularly as further operating cost leverage flows through.”

Richards said he expected new revenue streams to be generated in fiscal 2019 as a result of bolt-on acquisitions and expanded product distribution.

Strong foundations laid in 2018

Apiam should reap the benefits of its internal initiatives, as well as experiencing robust earnings growth from acquisitions made in 2018 in the coming 12 months.

The acquisition of two Victorian rural practices operating as the Terang and Mortlake Veterinary Clinic (TMVC) was the only acquisition completed in the first half of fiscal 2018.

The acquisition of these clinics enables the company to grow its existing presence in Victoria’s Western district, and importantly expand its dairy and beef offering (services, products, genetics) in this region.

TMVC has six veterinarians and is a diverse practice predominantly servicing the dairy industry, and is also active across the beef, equine and companion animal categories.

TMVC generated revenue of approximately $2.2 million in fiscal 2017, and based on the agreed acquisition terms, the TMVC acquisition is expected to be earnings accretive for Apiam shareholders in the first year of ownership.

Consequently, while making a small contribution in fiscal 2018, revenues from TMVC will have a much more substantial impact in fiscal 2019.

The other acquisitions only had a nominal impact in fiscal 2018 as they were finalised in the second half.

Expect the joint venture with PETstock and the acquisitions of Gympie and District Veterinary Services (Queensland) and Passionate Vetcare (Victoria) which were closed in June and February respectively to have a much larger impact in fiscal 2019.

Strengthening its global presence

Another positive will be the exclusive distribution agreement struck with Plumbline Life Sciences in August.

It is a leading Korean based animal DNA therapeutics company, and Apiam will exclusively distribute a number of its patented immunotherapy technology products in Australia and New Zealand, as well as having first right of refusal for exclusive distribution of future products in a range of markets.

Commenting on this development, Richards said, “Apiam is well positioned to commercialise Plumbline’s innovative technology across our animal footprint, initially in pigs and dairy cattle.

“We have a number of similar relationships under development and expect to continue leveraging new products across our client base in Australia and the US, via our new joint venture company, Apiam Solutions LLC”.

While early-stage revenues will be nominal, distribution of the products has the potential to significantly increase group gross margins.

Further to this development, Apiam recently established a US distribution company, Apiam Solutions LLC, based in Minnesota with joint venture partner, Swine Veterinary Center (SVC).

SVC is one of the largest and well known swine veterinary groups in the world, servicing a significant percentage of the US market as well as consulting in a number of other countries.

The partnership between Apiam and SVC, a long-term shareholder in Apiam, will see products developed by Apiam being distributed through the joint venture company in the US.

SVC will provide technical, administrative and local management support.

Products are expected to start flowing into the market in the second quarter of fiscal 2019 and the business is expected to be cash flow positive in its first year.

The establishment of Apiam Solutions LLC also provides a pathway for commercialisation and distribution to the US pig industry as Plumbline’s pig products are approved for use in North America over the next few years.

PETstock extends vertically integrated strategy

In February 2018, Apiam announced that it had entered into a joint venture alliance agreement with PETstock, a leading specialist petcare provider.

This will not only provide additional revenue streams, but add another link to Apiam’s vertically integrated business model, assisting it in the vital area of supply chain management.

Under the agreement, Apiam and PETstock will open a number of new veterinary clinics to be co-located at various PETstock retail outlets.

The co-located clinics will be jointly owned, with Apiam as an 80% shareholder and PETstock as a 20% shareholder.

The first co-located clinic, the General Practice, Emergency and Referral Centre at PETstock’s superstore in Bendigo (Epsom), opened in March 2018.

It has outperformed early stage revenue expectations, achieving around double the amount of revenue forecast for its first quarter of operations.

A second co-located clinic opened at PETstock Golden Square (also in Bendigo) in mid-August 2018, with additional clinics to be rolled out in targeted regional and rural locations throughout fiscal 2019.

Price target implies significant upside

While Apiam’s shares have increased 20% to 64 cents in the last week, they are coming off a relatively low base, and given the consensus 12 month price target is 80 cents some brokers must be expecting further upside.

The price target which implies share price upside of 25% appears achievable as it represents a forward price-earnings multiple (PE) of 13.8 relative to fiscal 2019 consensus forecasts.

This is a significant discount to the sector average multiple of 18.3, suggesting that there is also scope for a PE based rerating.

Though the major ASX listed player in the sector, Greencross Ltd (ASX:GXL) is currently trading on a forward multiple of 12.6, consensus forecasts for fiscal years 2019 and 2020 imply subdued growth of 1% and 5.4% respectively.

By comparison, Apiam’s consensus forecasts imply growth of 21.4% and 15.5% in fiscal years 2019 and 2020 respectively.

Perhaps the considerable publicity regarding drought affected regions has placed a drag on Apiam’s share price, but as the following graphic shows the company’s diversification is such that it is still achieving robust like-for-like revenue growth.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free